Daily Cardiology Research Analysis
Analyzed 57 papers and selected 3 impactful papers.
Summary
Analyzed 57 papers and selected 3 impactful articles.
Selected Articles
1. Association of Elective Peripheral Vascular Intervention with Outcomes Among Patients with Peripheral Arterial Disease and Intermittent Claudication.
In a 26,716-patient propensity-matched cohort, elective PVI for intermittent claudication was associated with higher major adverse limb events versus no PVI, including increased new major amputation, acute limb ischemia, and progression to CLTI. One in four patients underwent repeat PVI within 2–12 months, and total costs were 70% higher in the PVI group.
Impact: This large real-world analysis challenges the routine use of elective PVI for claudication by demonstrating worse limb outcomes and higher costs than conservative management.
Clinical Implications: Prioritize guideline-directed medical therapy (exercise therapy, risk factor control, antiplatelet/statins) and careful patient selection; use shared decision-making and consider deferring elective PVI for claudication absent limb-threatening ischemia.
Key Findings
- Elective PVI was associated with higher major adverse limb events versus no PVI (IRR 2.20, 95% CI 2.04–2.38).
- Increased risks included new major amputation (IRR 4.01), acute limb ischemia (IRR 1.94), and progression to CLTI (IRR 2.43).
- Among PVI recipients, 26.0% underwent repeat revascularization during months 2–12.
- Mean total cost of care was higher with PVI ($44,934 vs $26,452; cost ratio 1.70).
Methodological Strengths
- Large, nationally representative administrative dataset with 1:1 propensity score matching to balance key confounders.
- Hard clinical endpoints (MALE components) and cost analyses with standardized definitions.
Limitations
- Observational design with potential residual confounding and selection bias despite matching.
- Claims-based data lack anatomical lesion details, symptom severity, and functional outcomes; generalizability limited to insured U.S. populations.
Future Directions: Prospective comparative effectiveness trials testing supervised exercise therapy and optimal medical therapy versus selective PVI, with patient-reported outcomes, perfusion imaging, and cost-utility endpoints.
BACKGROUND: Peripheral vascular intervention (PVI) is increasingly used for the treatment of peripheral arterial disease (PAD) with intermittent claudication. However, large, real-world comparative studies of the safety and effectiveness of PVI compared with no PVI are limited. We sought to compare the effectiveness and costs of elective PVI compared to no PVI among patients with PAD and intermittent claudication. METHODS: We conducted a 1:1 propensity-matched retrospective cohort analysis of commercially insured and Medicare Advantage patients in OptumLabs® Data Warehous
2. Metabolic vulnerability index and Life's Essential 8 with risk of major adverse cardiovascular events.
In 239,135 UK Biobank participants followed for a median 13.6 years, higher NMR-derived MVX independently increased MACE risk, while high cardiovascular health (LE8 ≥80) nearly halved risk. The combination of low LE8 and top-quartile MVX identified the highest-risk group (HR 2.84), with interaction and mediation analyses suggesting that improving LE8 may reduce events partly by lowering metabolic vulnerability.
Impact: This study links a metabolomics-based vulnerability index with a standardized lifestyle/health metric to sharpen population risk stratification and reveal modifiable pathways.
Clinical Implications: Combined MVX and LE8 assessment can refine risk prediction beyond traditional factors, identifying high-yield targets for aggressive prevention; emphasizing LE8 improvements may mitigate metabolically driven risk.
Key Findings
- Each unit increase in MVX was associated with higher MACE risk (HR 1.08, 95% CI 1.07–1.10).
- High cardiovascular health (LE8 ≥80) was associated with substantially lower MACE risk versus low LE8 (HR 0.44, 95% CI 0.41–0.47).
- Participants with low LE8 and MVX quartile 4 had the highest MACE risk (HR 2.84, 95% CI 2.60–3.12).
- Additive interaction for MACE and MI and mediation analyses suggest LE8 improvements may reduce events partly via lowering metabolic vulnerability.
Methodological Strengths
- Very large prospective cohort with long follow-up and adjudicated outcomes.
- Advanced statistical approach including joint-effects, interaction, counterfactual, and mediation analyses.
Limitations
- UK Biobank’s healthy volunteer bias may limit generalizability.
- Observational design cannot prove causality; NMR biomarker availability and residual confounding remain concerns.
Future Directions: External validation across diverse cohorts and implementation studies to integrate MVX+LE8 into risk calculators; interventional trials testing whether targeted LE8 improvements reduce MVX and events.
The metabolic vulnerability index (MVX) captures metabolic-inflammatory vulnerability, but its joint relevance with Life's Essential 8 (LE8) for major adverse cardiovascular events (MACE) is unclear. We analyzed 239,135 UK Biobank participants free of baseline MACE. MVX was calculated from six NMR-based biomarkers. LE8 scores were classified as low (<60), moderate (60-79), or high (≥80) cardiovascular health (CVH). Cox models evaluated associations of MVX and LE8 with incident MACE; joint-effect, interaction, counterfactual, and mediation analyses were conducted. Over a median 13.6 years, 17,146 MACE occurred. Higher MVX was associated with higher MACE risk (HR = 1.08, 95% CI: 1.07, 1.10), whereas high CVH was associated with lower risk compared to low CVH (HR = 0.44, 95% CI: 0.41, 0.47). Participants with low CVH and MVX Q4 had the highest risk (HR = 2.84, 95% CI: 2.60, 3.12). Additive interaction was evident for MACE and myocardial infarction. Counterfactual and mediation analyses suggested that better CVH could prevent a substantial proportion of events, partly through lower metabolic vulnerability. Combined MVX and LE8 assessment may improve cardiovascular risk stratification and support targeted prevention.
3. Long-term survival after percutaneous coronary intervention or coronary artery bypass grafting in patients with diabetes and multivessel disease.
In a nationwide cohort of 26,166 diabetic patients with multivessel CAD, CABG was associated with lower all-cause and cardiovascular mortality than PCI and a 0.9-year longer weighted median survival, with the greatest survival advantage in left main or three-vessel disease. Results were consistent across sensitivity analyses, despite marked regional variation in revascularization strategies.
Impact: Provides robust, contemporary, real-world evidence supporting CABG over PCI for diabetics with extensive CAD, complementing RCT data and quantifying survival gains.
Clinical Implications: For diabetics with left main or three-vessel disease, heart teams should preferentially consider CABG for long-term survival benefit, while addressing regional practice variation and patient selection.
Key Findings
- CABG was associated with lower all-cause mortality versus PCI (HR 0.80, 95% CI 0.76–0.84) and lower cardiovascular mortality (HR 0.73, 95% CI 0.68–0.78).
- Weighted median survival was 0.9 years longer after CABG overall; survival gains were greater in left main (+4.1 years) and three-vessel disease (+3.4 years).
- Findings were robust in sensitivity analyses (multivariable Cox and instrumental variable analyses), despite wide regional PCI:CABG variation.
Methodological Strengths
- Nationwide registry linkage with large sample and long follow-up; robust causal inference methods (IPTW, IV, multiple sensitivity analyses).
- Clinically meaningful endpoints and stratified analyses by disease extent (left main, three-vessel).
Limitations
- Non-randomized design with potential unmeasured confounding and selection bias.
- Limited granularity on coronary anatomy, surgical risk, completeness of revascularization, and medical therapy optimization.
Future Directions: Refined heart-team decision tools integrating anatomy, frailty, and patient preferences; prospective registries capturing completeness of revascularization and modern medical therapy.
OBJECTIVE: To compare mortality risks, survival times and regional differences after coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in patients with diabetes and multivessel disease (MVD) in a large nationwide cohort of patients. METHODS: The SWEDEHEART registry was used to identify 26,166 patients with diabetes and MVD who underwent PCI (n=16,739, 64.0%) or CABG (n=9,427, 36.0%) in Sweden from 2006 to 2020. Individual patient data from five mandatory national registries were merged. Inverse probability of treatment weig